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Background: Postthrombotic syndrome is characterized by a fibrotic vein injury following deep vein thrombosis (DVT).
We sought to quantify the change in vein wall thickness in patients who fail to resolve DVT by 6 months and whether
there were differences in blood or plasma levels of inflammatory proteins associated with venous remodeling.
Methods: Patients presenting with confirmed lower extremity DVT were prospectively recruited for this study. Duplex
imaging of the lower extremity venous system was performed, and blood was collected at entrance and repeat evaluation
with blood draw and ultrasound imaging at 1 and 6months. DVT resolution and thickness of the vein wall was quantified
by ultrasound imaging in each segment affected by thrombus, and a contralateral, unaffected vein wall served as a control.
Gene and protein expression of inflammatory markers were examined from leukocytes and serum, respectively. Analysis
of variance or Student t-tests were used, and a P < .05 was significant. N  10 to 12 for all analyses.
Results: Thirty-two patients (12 patients with DVT resolution at 6 months, 10 patients with persistent thrombus at 6
months, and 10 healthy controls) were compared. Both resolving and nonresolving DVT were associated with a 1.5- to
1.8-fold increased vein wall thickness at 6months (P .008) as compared with nonaffected vein wall segments. However,
the thickness of the affected segments was 1.4-fold greater in patients who had total resolution of the DVT by 6 months
than in patients who had persistent chronic thrombus 6 months after presentation (P  .01). There was a four- to
five-fold increased level of matrix metalloproteinase-9 (MMP-9) antigen in thrombosed patients compared with
nonthrombosed patient controls (P < .05), while Toll-like receptor-9 (TLR-9) gene expression was three-fold less than
controls (P< .05) at enrollment. D-dimer and P-selectin were higher in thrombosed as compared to controls at diagnosis
but not at 6 months. Both TLR-4 (marker of inflammation) and P-selectin gene expression were higher in leukocytes
from patients with chronic DVT compared with those who resolved at 1 month after diagnosis (P < .05).
Conclusions: This preliminary study suggests ongoing vein wall remodeling after DVT, measurable by ultrasound and
associated with certain biomarkers. At 6 months, the vein wall is markedly thickened and directly correlates with
resolution. This suggests that the vein wall response is initiated early following thrombus formation and persists even in
the presence of total resolution. (J Vasc Surg 2011;53:139-46.)Deep vein thrombosis (DVT) continues to affect
900,000 patients a year in the United States.1,2 Somewhere
between 30 and 50% of these patients will subsequently be
affected by postthrombotic syndrome (PTS), which is de-
fined clinically by the presence of leg swelling, pain, and
ulceration.3,4 Despite best medical management with anti-
coagulation, many will be affected by PTS.4 Once these
symptoms begin, there is no specific treatment for the
pathologic changes that occur within the vein wall, and
treatment is entirely supportive, consisting of compression
therapy and wound care if ulcers develop.5
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doi:10.1016/j.jvs.2010.07.043The process of thrombus resolution in humans is still
unclear, in part due to lack of human deep vein pathological
specimens for study. While the association between DVT
and postthrombotic changes is well recognized,6 the pro-
gression from acute thrombosis to chronic fibrosis is still
unclear. Multisegment DVT, recurrent DVT, and early
onset of symptoms predict long-term PTS.4 Predicting
those patients with acute DVT who may develop PTS is
important for focusing aggressive therapy such as pharma-
comechanical thrombolysis (PMT) to maximize benefit to
risk and therapeutic success.7
Several reports have correlated serum inflammatorymark-
ers, such as intracellular adhesion molecular-1 (ICAM-1) and
C-reactive protein (CRP), with development of venous
insufficiency and PTS.8 Although not necessarily causal,
there is evidence from animal models to suggest the impor-
tance of the inflammatory response in the process of throm-
bus resolution.9 In a model of stasis DVT, prolonged
thrombus-vein wall contact is associated with most severe
vein wall injury.10 The cell adhesion molecule, P-selectin, is
also involved with vein wall injury and is also a marker of
thrombosis.11,12 Modification of the postthrombotic vein
wall injury response is possible with P-selectin inhibition.11
In order to characterize circulating markers of vein wall
injury after DVT and correlate this with thrombus resolu-
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undertook a prospective study of patients with acute DVT
and hypothesized that certain biomarkers would be ele-
vated and vein wall thickening would be greater in those
with chronic DVT as a marker of greater injury, as com-
pared with those who resolved their DVT within 6 months.
METHODS
Patient enrollment. Patients 18 years old, but you-
nger than 80 years of age, presenting to the diagnostic
vascular unit at the University of Michigan with signs and
symptoms of acute DVT were enrolled and agreed to
undergo repeat vascular ultrasound and phlebotomy. The
study was approved by the University of Michigan Institu-
tional Review Board for Human Subjects Research and
informed consent was obtained.
Inclusion criteria included those with an acute DVT in
the popliteal, femoral or iliac system, who had at least an
estimated 6months to live, no known prior history of DVT,
and were able to try to make follow-up appointments.
Anticoagulation was heparin, either low-molecular-weight
(LMWH) or unfractionated heparin (UFH), followed by a
vitamin K antagonist (VKA), and was directed by their
admitting or treating physician. Exclusion criteria included
those with a prior history of DVT, limited life expectancy,
and inability to give consent.
Note that healthy controls were those with no history
of DVT or any current DVT. This group was used for
comparison of serum and leukocyte gene expression with
those affected by an acute DVT. For duplex ultrasound
comparisons, vein wall thickness determination was within
the DVT groups, such that each patient was their own
control. Thus, only for vein wall imaging comparison was
the same patient used as their own control to decrease bias
from inherent baseline vein morphology differences.
Blood collection and storage. On enrollment in the
study, patients underwent phlebotomy of 5 to 10 mL of
blood. Of this, 2.5 mL was collected in PaxGene (BD
Biosciences, Becton Lakes, NJ) storage tubes, and 5 mL
was fractionated with processing and analysis of the plasma
fraction.
Diagnostic vascular ultrasound. The initial duplex
study and patient accrual took place in an Intersociety
Commission for Accredition of Vascular Laboratories cer-
tified vascular laboratory as entry point and is the only
vascular lab at the University of Michigan. Duplex ultra-
sonography was performed to evaluate the presence of
acute DVT. The limbs were evaluated by the standard
protocol for those with a clinical suspicion of DVT, prior to
consideration for study inclusion. Tissue Doppler imaging
(TDI) was performed to define the presence of thrombus
with a linear multi-hertz (7.5 MHz) transducer with the
Siemens Sonoline Antares (Siemens Medical Systems Inc,
Issaquah, Wash) unit, the Toshiba Aplio (Toshiba Ultra-
sound Systems SSA 790, Otawara, Japan) unit, and
Zonare Z.one (ZONARE Medical Systems Inc, Moun-
tain View, Calif) unit. Typical criteria for a clinical hu-
man evaluation of DVT were used, including a lack ofcompression, absence of flow, presence of dilated vein
void of echoes (acute), and presence of a shrunken vein full
of echoes (chronic).13 Images were performed in the sag-
ittal and transverse planes in a detailed fashion. In the
contralateral limb, similar imaging was done and recorded.
After the diagnosis of DVT was confirmed, follow-up du-
plex ultrasound was performed at 1 and 6 months (2
weeks). At the time of the follow-up appointments, duplex
images were obtained in the transverse and sagittal scan
planes at each segment of the initially affected vein bilater-
ally, including the nonaffected contralateral side (three
segments along affected and nonaffected vein per patient).
Notation of location and extent of the DVT was made at
initial enrollment scan to allow for the same venous seg-
ment evaluation at follow-up. All follow-up images being
analyzed were obtained in grayscale.
Image analysis was conducted using an open-source
DICOM viewer (Osirix, Pixmeo-Sarl., Switzerland). Fol-
lowing the completion of a pilot study where interobserver
reliability (90%) was confirmed by measurements of three
independent, blinded observers (PH, NB, KD), measure-
ments of the vein walls were conducted in a standardized
fashion. Three separate measurements of the most clearly
identified vein wall in each segment of interest were made,
recorded, and averaged by two independent observers (NB,
KD), to provide a vein wall thickness measurement for each
segment. For purposes of analysis, segments were com-
pared with nonaffected contralateral vein segments in the
same patient. Both affected and nonaffected veins were
imaged in the common femoral, femoral, and popliteal
veins of each patient analyzed.14,15
Bioplex enzyme-linked immunosorbent assay (ELISA).
After centrifugation, patient plasma was aliquoted and fro-
zen at70°C for storage. Quantification of peptides of inter-
est was performed using a Bioplex multiantigen ELISA (Bio-
rad, Hercules, Calif).16,17 Antigens of interest were CRP,
secondary leukocyte chemokine (SLC), P-selectin, D-
dimer,matrixmetalloproteinase (MMP)-2, and interleukin-
6 (IL-6). Results were standardized to the total amount of
protein in the sample, by a commercially available modified
Bradford assay using serial dilutions of bovine serum albu-
min as a standard (Pierce, Inc, Rockford, Ill).
Real-time polymerase chain reaction. A sample of
the collected blood was placed in PAXgene Blood RNA
System collecting tubes (BD Biosciences, Becton Lakes,
NJ) according to the manufacturer’s instructions. The
mRNA obtained was subject to reverse transcription by
incubation with Oligo-dT primer and M-MLV reverse
transcriptase (Life Technologies, Carlsbad, Calif) at 94°C
for 3 minutes and then incubated at 40°C for 70 minutes.
The cDNA obtained was amplified using TaqPolymerase
(Promega, Madison, Wisc) in the Rotor-Gene quantitative
real-time polymerase chain reaction system (Quiagen,
Hilden, Germany). SYBR green intercalating dye was used to
monitor levels of DNA amplification for each gene.18 Com-
mercially available primers were purchased for the following
genes of interest: B-Actin RefSeq# NM_001101.3, CRP
RefSeq# NM_000567.2, IL-6 RefSeq# NM 000600.3,
ho d
ection
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004530.2, SELP, RefSeq# NM_003005.3, SELPLG
RefSeq# NM_003006.3, TLR4 RefSeq# NM_138554.3,
and TLR9 RefSeq# NM_017442.2.
Statistical analysis. Comparisons were made between
groups by analysis of variance and paired and unpaired t-
test where appropriate. A P  .05 was considered signifi-
cant. The data are derived from 10 controls, 12 resolved
DVT, and 10 nonresolved DVT patients.
RESULTS
Acute DVT is associated with vein wall thickening.
Demographics of the patients are listed in the Table, and no
significant differences were found between groups. No
patients in those presenting with a DVT had a documented
recurrent DVT at 6-month follow-up, based on symptoms
Fig 1. A, Example of grayscale image of unaffected con
a postthrombotic thickened vein wall segment in a patien
vein wall hyperechogenicity.C,Vein wall thickness in non
D, Comparison of patient’s vein wall thickness in those w
Table. Patient characteristics
Characteristic Control (10)
Female (%) 5 (50)
Age 49 (3.2)
Weight 190.7 (14.6)
White (%) 8 (80)
Smoker (%) 1 (10)
Recent illnessa 1 (10)
Hypercoagulable 0
Wells criteria 2 (0.3)
Caprini score 3.6 (1.1)
Anticoagulation 0 (0)
aRecent illness included pneumonia, myocardial infarction, urinary tract infor ultrasound characteristics in follow-up studies. Not sur-prisingly, the Wells score19 and Caprini risk score20 were
higher in those with DVT than controls.
Segmental duplex analysis included the popliteal, fem-
oral, and common femoral veins. The segmental distribu-
tion of DVTwas similar between those who did and did not
resolve their DVT over 6 months. Patients with non-
resolved DVT had an average of 2.9  .34 vein segments
affected compared with 2.1  .33 vein segments in those
who fully resolved their DVT (P .09). All patients with a
DVT were treated with heparin anticoagulation, followed
by Coumadin. No patient had to prematurely stop their
anticoagulation. Lower extremity compression was at the
discretion of the treating physician, but neither compliance
with, nor strength of the compression, was assessed.
The affected vein wall segment thickness in patients
with acute DVT measured 1.5-fold greater than those in
eral vein image in longitudinal segment. B, Example of
h a resolved thrombus at 6 months. Arrows indicate the
mbosed subjects and those with an acute DVT over time.
id and did not resolve their DVT at 6 months. *P .05.
ved (12) Chronic (10) P value
7 (58) 3 (30) .69
1 (4.7) 59.9 (4.5) .21
3 (13.6) 186.5 (12.0) .78
2 (100) 10 (100) 1.0
1 (8.3) 0 (0) 1.0
8 (66) 7 (70) .99
1 2 .97
3 (1.5) 4.3 (1.5) .066
2 (0.6) 5.8 (1.0) .179
2 (100) 10 (100) .99







1unaffected contralateral nonthrombosed segments at the
VT v
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was even more profound, with a thickness 1.9-fold greater
than the measurable thickness in unaffected contralateral
nonthrombosed vein segments (P  .001; Fig 1, A-C).
There was no significant difference in the mean thickness of
the unaffected vein segments from patients with resolved or
nonresolved DVT at enrollment (data not shown). Af-
fected segments from patients with resolving thrombi were
modestly thicker than those from patients with chronic
thrombi at enrollment, with a significant difference
achieved at 6 months (P  .011; Fig 1, D).
Plasma from patients with DVT at enrollment con-
tains higher levels of MMP-9 and D-dimer. Plasma
from patients with acute DVT had circulating MMP-9
levels in plasma that were 4.2-fold higher than healthy
non-DVT controls (P  .008; Fig 2, A). Not surprisingly,
circulating levels of D-dimer were two-fold higher in DVT
patients than in healthy non-DVT controls, consistent with
D-dimer as a sensitive (although not specific) measure of
DVT19 (P  .04; Fig 2, B).19 However, no differences
between controls and those with an acute DVT in leuko-
cyte gene expression ofMMP-9, P-selectin, IL-6, or TLR-4
were found (data not shown).
Serum biomarkers at enrollment and over time in
patients with resolved versus chronic DVT. Patients
with acute DVT as compared with non-DVT controls had
Fig 2. A, Comparison of serum MMP-9 in patients
B, Comparison of serum D-dimer in subjects without D
Fig 3. A, P-selectin trended toward an increase at e
B, P-selectin was higher at 1 month in those patients w
chronic thrombus. *P  .05.higher levels of circulating P-selectin, as measured byELISA (Fig 3, A). Patients with complete resolution of
DVT had higher levels of circulating P-selectin at 1 month
than patients with chronic thrombus (P  .041; Fig 3, B).
By 6 months, there were no differences in circulating
P-selectin between patients with resolution and patients
with chronic occlusion (data not shown). Sera levels of IL-6
and MMP-9 were not different at enrollment or over time
between those who resolved and those who did not (data
not shown).
Leukocyte gene expression at enrollment and over
time in patients with resolved versus chronic DVT.
Given the lack of vein wall pathologic specimens to evalu-
ate, we analyzed gene expression of peripheral leukocytes in
study patients. Leukocytes are critical for DVT resolution
as well as playing a role in thrombogenesis, experiment-
ally.10,21 Circulating leukocytes in patients with acute DVT
demonstrate significant alterations in the expression of
genes associated with inflammation. Patients with acute
thrombosis have only 45% of the level of P-selectin ligand
gene expression (SELPG) of non-DVT controls (P 
.0012; Fig 4, A). Toll-like receptor-9 (TLR-9) expression
in circulating leukocytes from patients with acute DVT was
only 18% of that in non-DVT controls (P  .0001; Fig 4,
B). There were no significant differences in the leukocyte
gene expression profiles of MMP-9, MMP-2, P-selectin, or
IL-6 at enrollment between controls and acute DVT pa-
ut DVT as compared with patients with acute DVT.
ersus DVT patients. *P  .05.
ment, but no difference was observed at 6 months.
esolved their DVT as compared with those who had awithonroll
ho rtients (data not shown).
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DVT had lower levels of P-selectin gene expression (P 
.01; Fig 4, C) at enrollment, as compared with those with
chronic thrombosis. However, these differences had abro-
gated by 1 month, and levels remained similar at 6 months.
Additionally, the circulating leukocytes from patients who
had a resolved thrombus at 6 months expressed lower levels
of TLR-4 gene expression at enrollment (P .019), but no
differences were observed at 1 or 6 months. As compared
with those who resolved and did not resolve their DVT, no
differences were observed in leukocyte gene expression at
enrollment or at 1- or 6- month follow-up of IL-6, TLR-9,
MMP-2, or MMP-9 (data not shown).
DISCUSSION
In this prospective pilot study, we have shown via gene,
serum, and ultrasound measures, several important associ-
ations between patients with acute DVT, those with DVT
resolution, and those with persistent occlusive DVT at 6
months following initial thrombosis. To be able to predict,
using biomarkers and thrombus characteristics, those most
likely not to spontaneously recanalize would be beneficial,
not only to determine length of anticoagulation, but also
those most likely to gain benefit from PMT.7,22 A recent
retrospective study suggests the number of eligible patients
for PMT may be smaller than anticipated;23 thus, patient
selection is paramount. Further, treatment with LMWH
compared with VKAmay also decrease the risk of PTS.24 As
the extent and duration of thrombosis have previously been
shown to correlate with the risk of PTS, patients with
Fig 4. A, Peripheral leukocyte P-selectin ligand gene
non-DVT subjects at enrollment. B, TLR-9 expression
subjects at enrollment. C, P-selectin was increased at en
with those with chronic thrombus.D,TLR-4 expression
thrombus. *P  .05.chronic DVT may have higher long-term risk5 as well asgreater disability.25 These same patients also have higher
risk of recurrent DVT.26,27 Lastly, many patients have
evidence of PTS by 1 month after an inciting DVT, and
early events predict long-term results.4
The finding that vein wall thickness was greater early in
those segments affected by DVT supports the hypothesis
that alterations in the vein wall (which can be of the
extracellular matrix, the cellular fraction, or both) are a
direct result of the DVT, rather than simply venous hyper-
tension, which usually occurs over time.28 However, it is
possible patients with thicker vein walls are primarily more
likely to develop DVT. Contrary to our initial hypothesis,
those who resolved their DVT had a thicker vein wall at 6
months. This may reflect scarring in those segments as the
thrombus resolved, with thrombus adherence, luminal
opening, and fibrosis. Conversely, those with chronic DVT
may have a thinner vein wall due to incomplete thrombus
resolution, whereby the thrombus does not fully attach to
the vein wall, and thus full resolution does not occur. The
vein wall itself is a source of plasmin and other proteases/
proteinases that promote thrombus resolution.9,29 Al-
though by different pathology, venous varicosities show
increases in histologically measured vein wall thick-
ness.15,30 Vein wall thickening has been observed in a stasis
rat model of DVT, and the vein wall damage is greater with
prolongedDVT contact, but no determination of thickness
has yet been made in this model to corroborate the human
data.10
We differentiated vein wall thickness from persistent
thrombus by the following measures: first, we used stan-
ression was reduced in DVT patients compared with
reduced in DVT patients as compared with non-DVT
ent in those who resolved their thrombus as compared
duced at enrollment in those patients who had persistentexp
was
rollm
was redard criteria of thrombus echogenicity, and one primary
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Second, a pilot analysis evaluating the inter-observer
reliability of vein wall segment measurements was per-
formed, confirming reproducibility. Third, standardized
criteria for evaluating the vein wall and thrombosis were
developed prior to the initiation of this study. For exam-
ple, in areas of persistent thrombosis, the wall is visual-
ized as a more hyperechoic structure than adjacent
thrombus. Only areas with clearly observable transition
from a hypoechoic (thrombus) to hyperechoic (wall)
area were measured, and when necessary, comparisons
between longitudinal and transverse sections were made.
Additionally, observers were trained to identify and fol-
low the vein wall throughout the course of the ultra-
sound image, yielding reliable vein segments for analysis.
Finally, comparative areas on the nonaffected side were
made to account for individual patient differences. While
vein wall thickening is clinically apparent to surgeons
treating venous disease operatively, no reported attempt
to quantify this change has been made to date. We did
not specifically assess for valvular reflux in this group, as
this measure per se does not correlate with PTS or
severity, while chronic obstructing DVT does.25,31,32
While elevation of serum P-selectin and D-dimer were
not surprising in those with acute DVT as compared with
patients without DVT,12 the elevation of serum circulating
MMP-9 is novel. The association of venous pathology with
elevated MMP-9 expression, however, has been observed
in human injured veins.33-35 Additionally, serum levels
of MMP-9 have been shown to be elevated in other
nonthrombotic venous injury, including varicose veins
and venous stasis ulcers.36,37 Experimental data suggest
that MMP-9 may play a role in DVT resolution and
possibly vein wall injury.10,29 In the vascular system,
MMP-9 has elastinolytic and collagenolytic (primarily
Type IV) activity.38 Thus, inflammatory cells that invade
the perithrombotic space may release MMP-9 (activated by
plasmin) and mediate vein wall injury. However, as no
differences in MMP-9 gene or serum levels were found at
enrollment nor at later time points between resolved and
chronic DVT, this suggests this proteinase is likely most
important acutely. Recent experimental studies suggest
that genetic deletion of MMP-9 is associated with less vein
wall collagen deposition but does not seem to play a role in
DVT resolution (K. Barry Deatrick, unpublished data,
2010).Which cells release theMMP-9 are not defined from
the current study, but is likely from circulating leukocytes.
Since thrombosis is associated with a localized sterile
immune response,9 we have examined the response of the
innate immune system, mediated by Toll-like receptors, in
response to thrombosis.39 Expression of the receptor
TLR-9 was significantly downregulated in patients with
DVT, as compared with healthy patients without thrombo-
sis. Although we cannot say whether this association repre-
sents a causal interaction, it does imply a relationship be-
tween the innate immune response and the host reaction to
thrombosis. For example, the occurrence of DVT may
impair TLR-9 signaling processes, inhibiting the resolutionof sterile inflammation. Alternatively, impaired TLR-9 sig-
naling may predispose to clinical DVT. Recent experimen-
tal data suggest that genetic deletion of TLR-9 is associated
with impaired thrombus resolution. (PK Henke, paper in
submission). As TLR-4 is an innate receptor for lipopoly-
saccharide as well as inflammation, it is not immediately
clear why this marker was elevated in those patients with
chronic DVT.
P-selectin has been long studied by our group and is
both a sensitive and specific biomarker for DVT,12 as well as
causal in some models of experimental thrombosis.11,40 In
the current study, P-selectin was elevated early in patients
with DVT as compared with normal patients without
thrombosis and confirms similar findings in a prior study.12
Interestingly, leukocyte P-selectin ligand (SELPG, the P-
selectin receptor) gene expression was decreased in the
setting of acute thrombosis. Again, whether the elevation
of P-selectin and reduction of P-selectin ligand implies a
causal relationship to DVT, or whether this pattern is only
associated with the process of DVT resolution is not di-
rectly addressed in this study. However, as patients who
resolved their DVT had higher serum P-selectin at 1 month
after enrollment, this suggests that active thrombus metab-
olism is occurring compared with those with a chronic
thrombus.
Limitations of this study include the relatively small
number of patients enrolled and short 6-month duration of
follow-up. Thus, the development and severity of PTS was
not able to be evaluated in this study. Secondly, although
all patients were on anticoagulation, compliance with long-
term anticoagulation was not directly assessed and is a
factor for both recurrence of DVT and PTS.41 All positive
patients in this segment of the study were treated initially
with therapeutic heparin or LMWH and transitioned to
oral vitamin K-antagonist (warfarin) therapy long term.
The risk of PTS, however, is not entirely eliminated even in
the presence of appropriate anticoagulation, and we were
not able to determine the level of anticoagulation or inten-
sity of compliance. Longer patient follow-up will allow
better assessment of the hard clinical endpoint of PTS using
quality-of-life measures. Finally, other systemic cofounders
such as active malignancy, infection, or other nontested
hypercoagulable disorders may have been present. Further,
our data do not allow us to say anything about causation –
namely, whether the ultrasound changes observed in the
vein wall are caused by or only associated with inflamma-
tion and the markers described here.
These data have several potential clinical applications.
First, good data exist that lack of recanalization of a proxi-
mal DVT is associated with a significantly increased risk of
severe PTS.4,32 Second, characterizing leukocyte and se-
rum biomarkers that correlate with resolution may allow
prediction of those who may develop PTS. Although very
preliminary, these data indicate increased gene expression
of P-selectin and TLR-4 are associated with chronic throm-
bosis. Similarly, patients with acute DVT have increased
serum MMP-9 levels and decreased TLR-9 and P-selectin
ligand leukocyte expression, as compared with non-DVT
JOURNAL OF VASCULAR SURGERY
Volume 53, Number 1 Deatrick et al 145subjects. Third, the ability to predict which patients are
predisposed to impaired thrombus resolution may allow
physicians to selectively treat only those patients most likely
to benefit with expensive, higher-risk therapies, such as
PMT. On a more immediate level, those with persistent
thrombus on ultrasonography should probably be main-
tained on anticoagulation, as compared with those without,
as the risk of recurrent DVT is significantly grea-
ter.26 Finally, long-term evaluation of the host response to
sterile inflammation (eg, TLR) may provide a mechanism
to accelerate DVT resolution without the hemorrhagic risk
of anticoagulation or thrombolysis.
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